Outcome of Raised Intraocular Pressure in Uveitic Eyes with and without a Corticosteroid-Induced Hypertensive Response

American Journal of Ophthalmology

Volumn 148, Issue 2, 2009, Pages

  Sallam, Ahmed ^a   Sheth, Hiten G ^a   Habot Wilner, Zohar ^a   Lightman, Susan ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; BRIMONIDINE; CORTICOSTEROID; DORZOLAMIDE; EYE DROPS; FLUOROURACIL; LATANOPROST; MITOMYCIN C; PREDNISOLONE; PROSTAGLANDIN DERIVATIVE; TRAVOPROST; TRIAMCINOLONE ACETONIDE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CATARACT EXTRACTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; EYE INFLAMMATION; EYE IRRITATION; FEMALE; FILTERING OPERATION; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; IRIDECTOMY; LENS IMPLANT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; TRABECULECTOMY; UVEITIS;

EID: 67650409771     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.02.032     Document Type: Article

References (33)

1. Herbert H.M., Viswanathan A., Jackson H., and Lightman S.L. Risk factors for elevated intraocular pressure in uveitis. J Glaucoma 13 (2004) 96-99
2. Merayo-Lloves J., Power W.J., Rodriguez A., Pedroza-Seres M., and Foster C.S. Secondary glaucoma in patients with uveitis. Ophthalmologica 213 (1999) 300-304
3. Raitta C., and Vannas A. Glaucomatocyclitic crisis. Arch Ophthalmol 95 (1977) 608-612
4. Liesegang T.J. Clinical features and prognosis in Fuchs' uveitis syndrome. Arch Ophthalmol 100 (1982) 1622-1626
5. Falcon M.G., and Williams H.P. Herpes simplex kerato-uveitis and glaucoma. Trans Ophthal Soc UK 98 (1978) 101-104
6. Takahashi T., Ohtani S., Miyata K., et al. A clinical evaluation of uveitis associated secondary glaucoma. Jpn J Ophthalmol 46 (2002) 556-562
7. Kok H., Lau C., Maycock N., et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 112 (2005) 1916.e1-1921
8. Young S., Larkin G., Branley M., and Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 29 (2001) 2-6
9. Androudi S., Letko E., Meniconi M., et al. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm 13 (2005) 205-212
10. Angunawela R.I., Heatley C.J., Williamson T.H., et al. Intravitreal triamcinolone acetonide for refractory uveitic cystoid macular oedema: long-term management and outcome. Acta Ophthalmol Scand 83 (2005) 595-599
11. Hodge W.G., Lachaine J., Steffensen I., et al. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. Br J Ophthalmol 92 (2008) 7-12
12. Warwar R.E., Bullock J.D., and Ballal D. Cystoid macular edema and anterior uveitis associated with Latanoprost use: experience and incidence in a retrospective review of 94 patients. Ophthalmology 105 (1998) 263-268
13. Smith S.L., Pruitt C.A., Sine C.S., et al. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand 77 (1999) 668-672
14. Wand M., Gaudio A.R., and Shields M.B. Latanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyes. J Cataract Refract Surg 27 (2001) 1397-1401
15. Bloch-Michel E., and Nussenblatt R.B. International study group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 103 (1987) 234-235
16. Armaly M.F. Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of 3 levels of response. Invest Ophthalmol Vis Sci 4 (1965) 187-197
17. Bernstein H.N., Mills D.W., and Becker B. Steroid-induced elevation of intraocular pressure. Arch Ophthalmol 70 (1963) 15-18
18. Garbe E., Le Lorier J., Boivin J.F., and Suissa S. Inhaled and nasal glucocorticoids and the risk of ocular hypertension or open-angle glaucoma. JAMA 277 (1997) 722-727
19. Cubey R.B. Glaucoma following the application of corticosteroids to the skin of the eyelids. Br J Dermatol 95 (1976) 207-208
20. Kalina R.E. Increased intraocular pressure following subconjunctival corticosteroid administration. Arch Ophthalmol 81 (1969) 788-790
21. Clark A.F., Lane D., Wilson K., et al. Inhibition of dexamethasone-induced cytoskeletal changes in cultured human trabecular meshwork cells by tetrahydrocortisol. Invest Ophthalmol Vis Sci 37 (1996) 805-813
22. Wilson K., McCartney M.D., Miggans S.T., and Clark A.F. Dexamethasone induced ultra-structural changes in cultured human trabecular meshwork cells. Curr Eye Res 12 (1993) 783-793
23. Snyder R.W., Stamer W.D., Kramer T.R., and Seftor R.E. Corticosteroid treatment and trabecular meshwork proteases in cell and organ culture supernatants. Exp Eye Res 57 (1993) 461-468
24. Becker B., and Mills D.W. Corticosteroids and intraocular pressure. Arch Ophthalmol 70 (1963) 500-507
25. Sung V.C., and Barton K. Management of inflammatory glaucomas. Curr Opin Ophthalmol 15 (2004) 136-140
26. Arcieri E.S., Pierre Filho P.T., Wakamatsu T.H., and Costa V.P. The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension. Eye 22 (2008) 179-183
27. Linden C., Nuija E., and Alm A. Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open-angle glaucoma and ocular hypertension. Br J Ophthalmol 81 (1997) 370-372
28. Camras C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a 6-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103 (1996) 138-147
29. Alm A., and Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% Latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102 (1995) 1743-1752
30. Watson P., and Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 103 (1996) 126-137
31. Camras C.B. CME and anterior uveitis with latanoprost use. Ophthalmology 105 (1998) 1978-1981
32. Chang J.H., McCluskey P., Missotten T., et al. Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema?. Br J Ophthalmol 92 (2008) 916-921
33. Ladas J.G., Yu F., Loo R., Davis J.L., et al. Relationship between aqueous humor protein level and outflow facility in patients with uveitis. Invest Ophthalmol Vis Sci 42 (2001) 2584-2588